It is important to note that besides targeting Nrf2, dimethyl fumarate and its metabolite monomethyl fumarate are potent agonists for the hydroxycarboxylic acid receptor 2 (HCAR2) and are approved for the treatment of multiple sclerosis [156,157,158]. The gene discussed is HCAR2; the disease is multiple sclerosis.